Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Ivy Nile took to Instagram to reveal she is featured in the newest HERS Magazine. The feature covers "Fighting, Family, and Fitness." ...
11h
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
While Trump spent much of his nearly two-hour speech in Michigan ’s Grand Rapids hurling insults and profanities at his ...
Stocktwits on MSN15h
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 PerformanceHims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback